Abstract
A growing number of dominantly inherited neurodegenerative disorders are associated with an expanded polyglutamine-encoding sequence. Alterations in gene expression have been described for several of these diseases. Many animal and cell culture models have been established. In order to generate gene expression profiles of model systems using microarray technology, the Hereditary Disease Array Group (HDAG) was formed. This collaboration helps participants to refine the design, methods, and analyses and to identify potential problem areas. The ultimate goal of HDAG is to elucidate the mechanisms by which expanded polyglutamine tracts contribute to neuropathogenesis. This conference review intends to describe this collaborative effort and highlight some of the issues relating to technical aspects, quality control and bioinformatics as well as therapeutic targets and human samples.
Keywords: Hereditary disease array group hdag microarrays, neurodegenerative disorders, polyglutamine-encoding, hintington disease, huntington disease, spinocerebellar ataxias, spinobulbar muscular atrophy drpla, gene expression, bioinformatics, target validation, disease markers
Current Genomics
Title: The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update
Volume: 2 Issue: 3
Author(s): Tim- Rasmus Kiehl, James M. Olson and Stefan M. Pulst
Affiliation:
Keywords: Hereditary disease array group hdag microarrays, neurodegenerative disorders, polyglutamine-encoding, hintington disease, huntington disease, spinocerebellar ataxias, spinobulbar muscular atrophy drpla, gene expression, bioinformatics, target validation, disease markers
Abstract: A growing number of dominantly inherited neurodegenerative disorders are associated with an expanded polyglutamine-encoding sequence. Alterations in gene expression have been described for several of these diseases. Many animal and cell culture models have been established. In order to generate gene expression profiles of model systems using microarray technology, the Hereditary Disease Array Group (HDAG) was formed. This collaboration helps participants to refine the design, methods, and analyses and to identify potential problem areas. The ultimate goal of HDAG is to elucidate the mechanisms by which expanded polyglutamine tracts contribute to neuropathogenesis. This conference review intends to describe this collaborative effort and highlight some of the issues relating to technical aspects, quality control and bioinformatics as well as therapeutic targets and human samples.
Export Options
About this article
Cite this article as:
Kiehl Rasmus Tim-, Olson M. James and Pulst M. Stefan, The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update, Current Genomics 2001; 2 (3) . https://dx.doi.org/10.2174/1389202013350878
DOI https://dx.doi.org/10.2174/1389202013350878 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Mitochondrial Aconitase in Neurodegenerative Disorders: Role of a Metabolism- related Molecule in Neurodegeneration
Current Drug Targets Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Focus on the Correlations between Alzheimer’s Disease and Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Chaperonin GroEL: Structure and Reaction Cycle
Current Protein & Peptide Science Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology The Role of Mitochondrial Dysfunction in the Progression of Alzheimer’s Disease
Current Medicinal Chemistry Human Tooth Germ Stem Cells Preserve Neuro-Protective Effects after Long-Term Cryo-Preservation
Current Neurovascular Research Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy A Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic Disorders
Recent Patents on Food, Nutrition & Agriculture Design and Screening Strategies for α-Glucosidase Inhibitors Based on Enzymological Information
Current Topics in Medicinal Chemistry Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Redox State, Oxidative Stress, and Molecular Mechanisms of Protective and Toxic Effects of Bilirubin on Cells
Current Pharmaceutical Design PEGylated Chitosan Biodegradable Nanoparticles Delivery of <i>Salvia officinalis</i> and <i>Melissa officinalis</i> for Enhanced Brain Targeting
Current Nanomedicine